GlassScriptPhysician profile
Jodi Wimmer
NPI 1336740695
$1,992.98
in general payments reported to CMS, 2019-2025
29 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.41 · 2022: $193 · 2023: $734 · 2024: $522 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.53 | 2021-2025 | |
| Lilly USA, LLC | $189.79 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $174.46 | 2023-2025 | Otezla, Repatha, Evenity |
| Tris Pharma INC | $81.93 | 2023-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $66.61 | 2023-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $43.94 | 2023-2024 | Spravato, Xarelto |
| Novo Nordisk INC | $42.55 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $40.32 | 2022-2024 | Airsupra |
| Cranial Technologies, INC | $36.04 | 2023-2024 | Doc Band |
| Dynavax Technologies Corporation | $35.64 | 2022-2023 | Heplisav-B |
| Corium, LLC | $32.69 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $31.92 | 2023 | Shingrix, Arexvy |
| Pfizer INC. | $28.95 | 2023-2024 | |
| Axsome Therapeutics, INC. | $27.76 | 2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.84 | 2023 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $24.71 | 2025 | Flexitouch Plus, Nimbl |
| Boston Scientific Corporation | $21.14 | 2023 | Wavewriter Alpha Prime 16 |
| Edwards Lifesciences Corporation | $20.47 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Optinose US, INC. | $19.61 | 2025 | |
| Supernus Pharmaceuticals, INC. | $16.66 | 2023 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $16.31 | 2022 | |
| Amarin Pharma, INC. | $15.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2023 | Livalo, Seglentis |
| Almatica Pharma LLC | $15.33 | 2023 | Loreev Xr |
| Seqirus USA INC | $14.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.49 | 2023 | |
| Organon LLC | $14.38 | 2021-2025 | Nexplanon |
| Exact Sciences Corporation | $13.78 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Wimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.